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Results The SPIL and reference DXR HCl liposome 
injections exhibited generally comparable plasma and tis-
sue distribution profiles in both models. While minor dif-
ferences were observed between the two products in some 
tissues, different batches and lots of the reference product 
also showed some differences in the distribution of vari-
ous analytes in some tissues. The ratios of estimated free 
to encapsulated DXR for plasma and tissue were gener-
ally comparable between the SPIL and reference DXR 
HCl liposome injections in both models, indicating similar 
extents of absorption into the tissues and similar rates of 
drug release from liposomes.
Conclusions The plasma and tissue distribution pro-
files of the SPIL and reference DXR HCl liposome injec-
tions were shown to be generally comparable. Inconsisten-
cies between the products observed in some tissues were 
thought to be due to biological variation.
Keywords Anthracycline · Doxorubicin HCl liposome 
injection · Pharmacokinetics · Plasma distribution · 
Preclinical · Tissue distribution
Introduction
The use of doxorubicin (DXR), a potent chemotherapeutic 
agent, is limited in the clinical setting by its toxicity [1]. 
The cardiotoxicity caused by DXR is of special concern. 
Doxorubicin hydrochloride (HCl) liposome injection is a 
liposomal formulation of DXR that alters the plasma and 
tissue distribution of DXR, leading to an at least compara-
ble efficacy and an improved toxicological profile over non-
liposomal DXR [2–4].
Doxorubicin HCl liposome injection received approval 
from the US Food and Drug Administration (FDA) in 1995 
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for the treatment of AIDS-related Kaposi’s sarcoma. Since 
then, it has received worldwide approval for the treatment 
of multiple myeloma (combination therapy with bort-
ezomib) and ovarian carcinoma. In the European Union, 
it is additionally approved for patients with breast cancer 
who are at increased risk of DXR-associated cardiotoxicity 
[2, 5]. Janssen is currently marketing DXR HCl liposome 
injection as  Doxil® in the US and Japan and as  Caelyx® 
elsewhere.
Sun Pharmaceutical Industries Limited (SPIL) has 
developed a generic DXR HCl liposome injection (SPIL 
DXR HCl liposome injection). In February 2012, the FDA 
temporarily allowed the importation of Sun Pharma’s 
domestic liposomal DXR to cope with a  Doxil® drug short-
age, and because there were no approved generic alterna-
tives [6]. One year later, SPIL DXR HCl liposome injection 
was formally approved by the FDA.
This study was one of a program of studies, conducted 
in line with European Medicines Agency (EMA) guidance, 
to demonstrate similarity between the SPIL DXR HCl lipo-
some injection and  Caelyx®. The program included phys-
icochemical equivalence studies (structure, content and sta-
bility of liposomes in vitro and in vivo), which confirmed 
that the two liposomal forms are similar (SPIL data on file).
Caelyx® alters the plasma and tissue distribution of 
DXR, resulting in an improved benefit-risk profile as com-
pared with nonliposomal DXR. Therefore, SPIL DXR HCl 
liposome injection must achieve comparable plasma and 
tissue distribution in humans to be considered truly compa-
rable to  Caelyx® [2, 7].
Previously, we demonstrated that the preclinical anti-
tumour efficacy and toxicity profile and the extent of total 
DXR absorption of the SPIL DXR HCl liposome injection 
were comparable to  Caelyx® in relevant mouse models of 
cancer (Burade et al. Paper accepted by BMC Cancer sub-
ject to revision).
The objectives of the studies presented in this paper 
were to compare the plasma and tissue distribution of the 
SPIL DXR HCl liposome injection with the reference 
product  (Caelyx®) following single intravenous injec-
tion in syngeneic fibrosarcoma-bearing BALB/c mice and 
Sprague–Dawley rats. The plasma and tissue distribution of 
different batches and different lots of the same batch of the 




The SPIL DXR HCl liposome injection (SPIL, Halol, India) 
and reference DXR HCl liposome injection  (Caelyx®, 
Janssen-Cilag International NV, Beerse, Belgium) were 
stored at 2–8 °C. The SPIL and reference DXR HCl lipo-
some injections contained 2 mg/mL of the active ingredi-
ent, DXR HCl. The SPIL and reference DXR HCl liposome 
injections also contained N-(carbonyl-methoxypolyethylene 
glycol 2000)-1,2-distearoyl-sn-glycerol-3-phosphoethanol-
amine (mPEG-DSPE), hydrogenated soy phosphatidylcho-
line (HSPC), cholesterol, ammonium sulphate, l-histidine 
as a buffer, hydrochloric acid and/or sodium hydroxide for 
pH control, sucrose to maintain isotonicity and water for 
injection. All products were either used at 2  mg/mL, or 
diluted to the desired concentration in sterile 5% glucose 
solution.
Animals
The project proposal for the study was approved by the 
Institutional Animal Ethics Committee (IAEC), and their 
recommendations regarding animal care and handling were 
followed. Male BALB/c mice and male Sprague–Daw-
ley rats were supplied by Laboratory Animal Resources 
(LAR), Sun Pharma Advanced Research Company Lim-
ited (SPARC Ltd.). The BALB/c mice were 6–10  weeks 
of age at the time of receipt and weighed 25 ± 5  g. The 
Sprague–Dawley rats were 5–8 weeks of age and weighed 
150–180  g at receipt. For BALB/c mice, a veterinary 
health check was performed before tumour propagation to 
select healthy animals. For Sprague–Dawley rats, a veter-
inary health check was performed on day 0 of the study. 
The BALB/c mice and Sprague–Dawley rats used in the 
studies were housed in individually ventilated polysul-
fone cages. The BALB/c mice were housed individually, 
while Sprague–Dawley rats were housed two to three per 
cage. Cages were maintained under constant temperature 
(18–26 °C), humidity (30–70%) and lighting conditions 
(12 h light and 12 h dark). Animals received reverse osmo-
sis (RO) water supplied by LAR, and Harlan Teklad Rodent 
Diet 2018 ad libitum.
Cell lines
WEHI 164 cells suspended in phosphate buffer saline 
(1–2 × 107 viable cells per mL) were used for the induction 
of solid tumours. Briefly, male BALB/c mice were shaved 
with the help of a shaver and hair-removing cream, and 
inoculated intradermally on the shaved portion of dorsal 
skin with tumour cells. Calibrated digital Vernier calipers 
were used to measure tumour diameter in three perpendicu-
lar planes, after the tumours became palpable. Tumour vol-
ume was calculated using the formula for an ellipse, V = π/6 
(D1 × D2 × D3)  mm3, where D1/D2/D3 is the diameter 
(mm) in each of the three different planes.
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Study design
The respective designs of the plasma and tissue distribu-
tion studies are shown in Table  1. Fibrosarcoma-bearing 
male BALB/c mice were screened and selected for ran-
domisation into study groups on the basis of body weight 
and tumour volume. Selected animals weighed 22.2–30.5 g 
and had a tumour volume 150 ± 50 mm3 at randomisation. 
Male Sprague–Dawley rats were screened and selected 
for randomisation into study groups on the basis of body 
weight, and weighed 190.1–258.0 g at randomisation. The 
doses of SPIL and reference DXR HCl liposome injec-
tions used in these studies (BALB/c mice, 2.4 or 6 mg/kg; 
Sprague–Dawley rats, 4 or 10  mg/kg) were calculated to 
be equivalent to 20 or 50 mg/m2, respectively, in humans. 
Intravenous injections were administered on day 0. Blood 
samples for plasma distribution analysis were collected 
at 1, 4, 24, 48, 96, 168, 240, 336, or 672  h postinjection 
(Table  1). Animals were euthanised at this time in order 
to harvest the heart, skin, liver, kidney, spleen, lung, bone 
marrow and tumour (BALB/c mice only) for tissue distri-
bution analysis. Plasma was separated from blood samples 
by centrifugation. For BALB/c mice, plasma samples were 
pooled from four animals serially, providing three pooled 
samples for each time point. The tumour (BALB/c mice 
only), heart, skin, liver, kidney, spleen and lung were dis-
sected out from all animals. Both hind legs were dissected 
out for bone marrow preparation, which was scrapped and 
collected after cutting bones longitudinally using scalpel 
blades. All tissues were blotted on Whatman filter paper 
No. 1 to remove the blood. For BALB/c mice, samples of 
each tissue from four animals were pooled, providing three 
pooled samples per tissue for each time point (except bone 
marrow, where samples from all 12 animals were pooled 
for each time point). Tissue homogenates were prepared 
using a homogenizer. A 20% weight/volume (w/v) tissue 
homogenate was prepared for tumour (BALB/c mice only), 
heart, liver, kidney, spleen, lung and bone marrow. For 
skin, either a 10 or 20% w/v tissue homogenate was pre-
pared (2.4 mg/kg mouse study: a 10% w/v skin homogenate 
was prepared for all time points except at 96  h; 6  mg/kg 
mouse study: a 20% w/v skin tissue homogenate was pre-
pared; 4 mg/kg rat study: a 10% w/v skin homogenate was 
prepared for all time points except at 1 and 4 h; 10 mg/kg 
rat study: a 20% w/v skin tissue homogenate was prepared). 
Heart and skin tissues were minced before homogenization.
Experimental outcomes
Plasma drug levels were measured from the plasma sam-
ples for each time point by liquid chromatography–tandem 
mass spectrometry (LC-MS/MS), and reported as micro-
grams per millilitre (mcg/mL). Tissue drug levels were 
measured from tissue samples for each time point by 
LC-MS/MS, and reported as micrograms of DXR per gram 
of tissue (mcg/g of tissue). Plasma and tissue data were 
used to calculate the mean peak concentration (Cmax) and 
mean area under the curve from zero (0) hours to time (t) 
 (AUC0–t) of total DXR, encapsulated DXR, free DXR, and 
doxorubicinol. The ratio of estimated free to encapsulated 
DXR was defined as the estimated mean Cmax (or  AUC0–t) 
of free DXR divided by the mean Cmax (or  AUC0–t) of 
encapsulated DXR.
Statistical methods
The mean AUCs and 95% confidence intervals of the 
difference between every two groups were calculated 
by the Bailer–Satterthwaite method. A difference in 
AUCs was considered to be statistically significant when 
abs(tobs) ≥ tcrit. For mean Cmax, the 95% confidence intervals 
of the differences between every two groups were calcu-
lated by unpaired t-test. A difference in Cmax was consid-
ered to be statistically significant when p ≤ 0.05. Zero-hour 
concentration values were reported (as zero) for the pur-
pose of calculating AUC only. A statistical analysis of 
bone marrow derived from syngeneic fibrosarcoma-bear-
ing BALB/c mice was not performed, as only 1 value was 
available for each group (sample was pooled from 12 ani-
mals for concentration analysis owing to limited quantity).
Results
Plasma distribution of DXR in syngeneic 
fibrosarcoma-bearing mice
Mean plasma Cmax and  AUC0–t values for total DXR and 
doxorubicinol, following a single intravenous injection 
with either the SPIL or reference DXR HCl liposome injec-
tion in syngeneic fibrosarcoma-bearing BALB/c mice, are 
shown in Fig. 1.
Maximum concentration
In plasma, the mean Cmax values of total DXR (Fig.  1a), 
free and encapsulated DXR (data not shown) and doxorubi-
cinol (Fig. 1c) were comparable after 2.4 mg/kg SPIL com-
pared with 2.4 mg/kg reference DXR HCl liposome injec-
tion. The mean plasma Cmax values of total DXR (Fig. 1a), 
free DXR (data not shown) and doxorubicinol (Fig.  1c) 
were also comparable after 6  mg/kg SPIL and reference 
DXR HCl liposome injections. However, the mean plasma 
Cmax of encapsulated DXR was significantly lower after 
6 mg/kg SPIL DXR HCl liposome injection compared with 
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Table 1  Study design






Time point (h) No. of animals 
per time point
(a) Study groups for the syngeneic fibrosarcoma-bearing BALB/c mouse study (2.4 mg/kg dose)



















(b) Study groups for the syngeneic fibrosarcoma-bearing BALB/c mouse study (6 mg/kg dose)
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Table 1  (continued)






Time point (h) No. of animals 
per time point
(c) Study groups for the Sprague–Dawley rat study (4 mg/kg dose)





































(d) Study groups for the Sprague–Dawley rat study (10 mg/kg dose)
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the reference DXR HCl liposome injection (p = 0.0351; 
data not shown).
Area under the curve
The mean plasma  AUC0–t values of total DXR (Fig.  1b) 
and free and encapsulated DXR (data not shown) after 2.4 
and 6 mg/kg were comparable between the SPIL and ref-
erence DXR HCl liposome injections. However, the mean 
plasma  AUC0–t of doxorubicinol was significantly lower 
after 2.4  mg/kg SPIL DXR HCl liposome injection com-
pared with the reference DXR HCl liposome injection 
(tcrit = 2.4469 and tobs = −5.5357; Fig. 1d). This was not 
the case after 6 mg/kg, where the mean plasma  AUC0–t of 
doxorubicinol (Fig. 1d) was comparable between the SPIL 
and reference DXR HCl liposome injections.
Tissue distribution of DXR in syngeneic 
fibrosarcoma-bearing mice
Mean tissue Cmax and  AUC0–t values of total DXR and 
doxorubicinol (liver and heart) for syngeneic fibrosarcoma-
bearing BALB/c mice, following a single intravenous injec-
tion with either the SPIL or reference DXR HCl liposome 
injection, are also shown in Fig. 1.
Maximum concentration: total DXR
The mean Cmax of total DXR was comparable between the 
SPIL and reference DXR HCl liposome injections for all 
tissues after 2.4 mg/kg, except in the liver, where the Cmax 
was significantly lower for the SPIL compared with the ref-
erence DXR HCl liposome injection (p = 0.0018, Fig. 1a). 
The mean Cmax of total DXR was comparable between the 
SPIL and reference DXR HCl liposome injections for all 
tissues after 6 mg/kg.
Area under the curve: total DXR
The mean  AUC0–t of total DXR was not significantly differ-
ent for most tissues between the SPIL and reference DXR 
HCl liposome injections after 2.4 or 6  mg/kg (Fig.  1b). 
The exceptions were the kidney and liver  AUC0–t values 
after 2.4  mg/kg, which were significantly lower for the 
SPIL than for the reference DXR HCl liposome injec-
tion (tcrit  =  2.2281 and tobs  =  −3.5048 for the kidney, 
tcrit  =  2.3646 and tobs  =  −3.5231 for the liver), and the 
lung  AUC0–t values after 6 mg/kg, which were significantly 
higher for the SPIL than for the reference DXR HCl lipo-
some injection (tcrit = 2.3060 and tobs = 2.9502).
Table 1  (continued)
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DXR doxorubicin, HCl hydrochloride, SPIL Sun Pharmaceutical Industries Limited
a Repeat time points
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Maximum concentration: doxorubicinol
The mean Cmax of doxorubicinol was comparable between 
the SPIL and reference DXR HCl liposome injections in 
heart tissue, after 2.4  mg/kg. However, the mean liver 
Cmax was significantly lower for the SPIL compared with 
the reference DXR HCl liposome injection (p = 0.0005; 
Fig. 1c). The mean Cmax of doxorubicinol was compara-
ble between the SPIL and reference DXR HCl liposome 
injections in heart and liver tissue, after 6 mg/kg.
Fig. 1  Plasma and tissue 
distribution of total DXR and 
doxorubicinol in syngeneic 
fibrosarcoma-bearing BALB/c 
mice. a Cmax and b  AUC0–t of 
total DXR after dosing with 
the SPIL or reference DXR 
HCl liposome injection. c Cmax 
and d  AUC0–t of doxorubicinol 
after dosing with the SPIL or 
reference DXR HCl liposome 
injection. Twelve animals were 
analysed per time point. Each 
plasma sample was pooled 
from four animals, providing 
three pooled samples for each 
time point. Each tissue sample 
was pooled from four animals, 
providing three pooled samples 
per tissue for each time point 
(except bone marrow, where 
samples from all 12 animals 
were pooled for each time 
point). Differences in Cmax were 
analysed by unpaired t-test. P 
values ≤0.05 were considered 
significant. Differences in 
 AUC0–t were analysed by the 
Bailer–Satterthwaite method, 
and a difference was considered 
to be statistically significant 
when abs(tobs) ≥ tcrit. AUC area 
under the concentration–time 
curve, Cmax mean peak concen-
tration, DXR doxorubicin, ns not 
significant, SPIL Sun Pharma-
ceutical Industries Limited
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Area under the curve: doxorubicinol
The mean heart  AUC0–t values were comparable for the 
SPIL and reference DXR HCl liposome injections after 
either 2.4 or 6 mg/kg (Fig. 1d). The mean liver  AUC0–t 
values were comparable for 6 mg/kg SPIL and reference 
DXR HCl liposome injections, but a significantly lower 
liver  AUC0–t value was observed after 2.4  mg/kg SPIL 
compared with 2.4 mg/kg reference DXR HCl liposome 
injection (tcrit = 2.7765 and tobs = −4.0255). This reflects 
the same trend observed in plasma.
Fig. 1  (continued)
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Plasma distribution of DXR in Sprague–Dawley rats
Mean plasma Cmax and  AUC0–t values for Sprague–Dawley 
rats, following a single intravenous injection with either the 
SPIL or reference DXR HCl liposome injection, are shown 
in Fig. 2. At 4 mg/kg, the plasma distribution of the SPIL 
DXR HCl liposome injection was compared with 2 dif-
ferent batches of the reference product [batch 1 (B1) and 
batch 2 (B2)] and, at 10 mg/kg, with 2 different lots of the 
reference product [lot 1 (L1) and lot 2 (L2)]. The different 
batches and lots of the reference product were also com-
pared with each other.
Maximum concentration
In plasma, the mean Cmax values of total DXR were 
comparable between all three groups [SPIL and both 
batches (B1 and B2) of the reference product] at 4  mg/
kg. The mean plasma Cmax of encapsulated DXR was sig-
nificantly lower for the SPIL DXR HCl liposome injec-
tion compared with B1 and B2 of the reference product 
(p = 0.0126 and p = 0.0001); however, the Cmax values of 
B1 and B2 were also significantly different when com-
pared with each other (p = 0.0240). The mean plasma 
Cmax of free DXR was significantly higher for the SPIL 
Fig. 2  Plasma and tissue distribution of total DXR and doxorubicinol 
in Sprague–Dawley rats. a Cmax and b  AUC0–t of total DXR after dos-
ing with the SPIL or reference DXR HCl liposome injection. c Cmax 
and d  AUC0–t of doxorubicinol after dosing with the SPIL or refer-
ence DXR HCl liposome injection. Ten animals were analysed per 
time point. Differences in Cmax were analysed by unpaired t-test. P 
values ≤0.05 were considered significant. Differences in  AUC0–t were 
analysed by the Bailer–Satterthwaite method, and a difference was 
considered to be statistically significant when abs(tobs) ≥ tcrit. AUC 
area under the concentration–time curve, Cmax mean peak concentra-
tion, B1 batch 1, B2 batch 2, DXR doxorubicin, L1 lot 1, L2 lot 2, ns 
not significant, SPIL Sun Pharmaceutical Industries Limited
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DXR HCl liposome injection than for reference DXR HCl 
liposome injection B2 at 4  mg/kg (p = 0.0354). Also at 
4 mg/kg, the mean plasma Cmax of doxorubicinol was sig-
nificantly lower for the SPIL DXR HCl liposome injec-
tion compared with reference DXR HCl liposome injec-
tion B2 (p = 0.0217; Fig.  2c). The mean plasma Cmax 
values of all four analytes (total, free and encapsulated 
DXR, and doxorubicinol) were comparable between the 
SPIL and both lots (L1 and L2) of the reference DXR 
HCl liposome injection, at 10 mg/kg (Fig. 2a).
Area under the curve
The mean plasma  AUC0–t values of total DXR were com-
parable between the SPIL and reference DXR HCl lipo-
some injection B1 and B2 at 4  mg/kg. However, the 
 AUC0–t values of total DXR for the SPIL DXR HCl lipo-
some injection were significantly lower compared with 
reference DXR HCl liposome injection L1 at 10  mg/
kg (tcrit = 1.9955 and tobs = −2.7108; Fig. 2b). The mean 
plasma  AUC0–t values for doxorubicinol for the SPIL DXR 
Fig. 2  (continued)
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HCl liposome injection were significantly lower compared 
with reference product B2 at 4 mg/kg (tcrit = 2.00030 and 
tobs  =  −3.82304) and reference product L2 at 10  mg/kg 
(tcrit = 1.9908 and tobs = −2.3110). However, this was not 
the case for the SPIL DXR HCl liposome injection com-
pared with reference product B1 at 4 mg/kg and reference 
product L1 at 10 mg/kg, where plasma  AUC0–t values were 
comparable (Fig. 2d). Mean  AUC0–t for free DXR was sig-
nificantly higher for SPIL compared with reference DXR 
HCl liposome injection B2 at 4 mg/kg (tcrit = 2.0181 and 
tobs  =  2.0467). However, mean  AUC0–t for encapsulated 
DXR was significantly lower for SPIL compared with 
either reference DXR HCl liposome injection B1 or B2, at 
4 mg/kg. These findings suggest that at this dose, there may 
be a difference between the SPIL and reference DXR HCl 
liposome injections in plasma distribution of encapsulated 
versus free forms of DXR.
Tissue distribution of DXR in Sprague–Dawley rats
Maximum concentration: total DXR
Overall, the Cmax values of total DXR for most tissues 
were comparable between SPIL and each batch and lot 
of the reference DXR HCl liposome injection (Fig.  2a). 
The mean Cmax values of total DXR were significantly 
lower in the heart for the SPIL DXR HCl liposome 
injection compared with reference product B2, at 4  mg/
kg, and reference product L2, at 10  mg/kg (p = 0.0351 
and p = 0.0137, respectively). The mean Cmax values of 
total DXR in the kidney were significantly lower for the 
SPIL DXR HCl liposome injection compared with refer-
ence product B2, at 4 mg/kg, (p = 0.0089), and with ref-
erence product L1 and L2, at 10  mg/kg (p = 0.0044 and 
p = 0.0005). In lung tissue, mean Cmax values of total 
Fig. 2  (continued)
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DXR were also significantly lower for the SPIL than for 
the reference DXR HCl liposome injection L1 at 10 mg/
kg (p = 0.0019); however, the Cmax values of L1 and L2 
were also significantly different in the lung (p = 0.0002). 
The mean Cmax value of total DXR in the spleen was sig-
nificantly higher for SPIL compared with one of the refer-
ence DXR HCl liposome injection lots (L1; p = 0.0155).
Area under the curve: total DXR
Overall exposure to total DXR in the heart and kidney was 
similarly lower for SPIL compared with either of the ref-
erence DXR HCl liposome injections at 4 and 10  mg/kg 
(Fig. 2b). This was also true in the liver at 4 mg/kg, with 
significantly lower  AUC0–t for SPIL compared with refer-
ence DXR HCl liposome injection B1 and B2; however, 
Fig. 2  (continued)
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at 10  mg/kg, the SPIL DXR HCl liposome injection was 
comparable with reference product L1 and L2, in the 
liver. There was some evidence of differences between the 
 AUC0–t values for SPIL compared with those for one of 
the batches and lots of the DXR HCl liposome injection in 
some of the other tissues, but there was no obvious trend to 
this, and for some tissues, there was a significant difference 
between mean  AUC0–t values of reference product B1 and 
B2, and between mean  AUC0–t values of reference product 
L1 and L2.
Maximum concentration: doxorubicinol
The mean Cmax of doxorubicinol was comparable between 
the SPIL and reference DXR HCl liposome injections in 
liver tissue, after 4  mg/kg. However, the mean liver Cmax 
was significantly lower for 10  mg/kg SPIL compared 
with reference DXR HCl liposome injection L1 and L2 
(p = 0.0274 and p = 0.0315). The mean heart Cmax of doxo-
rubicinol was significantly lower for SPIL compared with 
reference product B1 and B2 at 4  mg/kg, and compared 
with reference product L1 and L2 at 10 mg/kg (Fig. 1c).
Area under the curve: doxorubicinol
The mean liver  AUC0–t values of doxorubicinol were com-
parable for the SPIL and reference DXR HCl liposome 
injections after either 4 or 10  mg/kg (Fig.  2d). A signifi-
cantly lower heart  AUC0–t value was observed for SPIL 
compared with reference product B1 and B2 at 4  mg/kg, 
and compared with reference product L1 and L2 at 10 mg/
kg.
Ratios of free to encapsulated DXR
The ratios of estimated free to encapsulated DXR for syn-
geneic fibrosarcoma-bearing mice and Sprague–Dawley 
rats, following a single intravenous injection with either the 
SPIL or reference DXR HCl liposome injection, are shown 
in Table  2. In syngeneic fibrosarcoma-bearing mice, the 
ratios of estimated free to encapsulated DXR for all the tis-
sues were comparable between the two products at 2.4 mg/
kg (Table 2a). At 6 mg/kg, the ratios of estimated free to 
encapsulated DXR were also comparable for all the tissues 
between the two products, except for minor differences in 
bone marrow, tumour and skin (Table 2b).
In Sprague–Dawley rats, the ratios of estimated free 
DXR to encapsulated DXR in plasma and all tissues exam-
ined were generally comparable between the SPIL DXR 
HCl liposome injection and each of the two batches of the 
reference product at 4 mg/kg (Table 2c), and between the 
SPIL DXR HCl liposome injection and each of the two lots 
of the reference product at 10 mg/kg (Table 2d).
Discussion
The availability of a generic DXR HCl liposome injection 
could potentially improve access to an important anticancer 
agent. Because the improved benefit-risk profile of  Caelyx® 
results from its altered tissue distribution, a generic liposo-
mal formulation of DXR must demonstrate a comparable 
plasma and tissue distribution [7]. As it is not possible to 
study tissue distribution in humans, in vivo nonclinical data 
are crucial to the regulatory decision of whether to approve 
a generic DXR liposomal product [7].
The objectives of the studies presented in this paper 
were to compare the plasma and tissue distribution of the 
SPIL DXR HCl liposome injection with the reference 
DXR HCl liposome injection following single intravenous 
injection in murine models. To compare the two products 
in a tumour background, a syngeneic fibrosarcoma mouse 
model was used.
In syngeneic fibrosarcoma-bearing BALB/c mice, the 
ratios of estimated free to encapsulated DXR for all the tis-
sues were comparable between the two products, except 
for minor differences in bone marrow, tumour, and skin at 
6 mg/kg. This indicates that the SPIL and reference formu-
lations have similar extents of absorption into the tissues 
and similar rates of drug release from liposomes. Despite 
some evidence of biological variations (especially in the 
liver and kidney), at 2.4  mg/kg, the SPIL and reference 
products showed generally comparable plasma and tissue 
distribution profiles in syngeneic fibrosarcoma-bearing 
BALB/c mice.
In Sprague–Dawley rats, the ratios of estimated free to 
encapsulated DXR for plasma and all tissues are compa-
rable between the SPIL DXR HCl liposome injection and 
the two batches and lots of the reference product, indi-
cating that the test and reference formulations have simi-
lar extents of absorption into the tissues and similar rates 
of drug release from liposomes. The minor differences 
observed between the SPIL and reference products in some 
tissues may be attributed to inherent biological variations 
of the test system, since two different batches of the refer-
ence DXR HCl liposome injection also showed some dif-
ferences. The SPIL and reference products exhibited gen-
erally comparable plasma and tissue distribution profiles 
in Sprague–Dawley rats. Even two different batches and 
lots of the reference DXR HCl liposome injection failed to 
show comparable distribution of all the analytes in all the 
tissues, suggesting any variations of tissue distribution may 
be caused by the inherent biological fluctuation of the test 
system.
Based on Cmax and mean  AUC0–t values, there was evi-
dence that the SPIL DXR HCl liposome injection may lead 
to lower exposure of the cardiotoxic metabolite doxorubi-
cinol in the heart in rats, and also some suggestion of the 
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Table 2  Ratios of free to encapsulated DXR
Tissues Free drug/encapsulated drug Cmax Free drug/encapsulated drug  AUC0–t
SPIL DXR HCl 
liposome injection
Reference DXR HCl liposome injection SPIL DXR HCl lipo-
some injection
Reference DXR HCl lipo-
some injection
(a) Ratios of free to encapsulated DXR in syngeneic fibrosarcoma-bearing mice (2.4 mg/kg dose)
 Plasma 0.03 0.03 0.04 0.03
 Bone marrow 1.4 1.5 5.3 4.4
 Tumour 0.1 0.1 0.2 0.4
 Skin 0.7 1.2 1.3 1.2
 Kidney 0.04 0.04 0.1 0.1
 Heart 0.2 0.1 0.1 0.1
 Spleen 0.08 0.1 0.1 0.1
 Lung 0.1 0.08 0.1 0.4
 Liver 0.08 0.06 0.2 0.1
(b) Ratios of free to encapsulated DXR in syngeneic fibrosarcoma-bearing mice (6 mg/kg dose)
 Plasma 0.02 0.02 0.03 0.03
 Bone marrow 1.4 0.5 3.9 1.9
 Tumour 0.3 0.1 0.4 0.2
 Skin 2.2 0.8 1.8 0.9
 Kidney 0.09 0.09 0.1 0.09
 Heart 0.3 0.3 0.5 0.4
 Spleen 0.5 0.4 0.8 0.8
 Lung 0.2 0.1 0.2 0.1
 Liver 0.2 0.2 0.5 0.4
Tissues Free drug/encapsulated drug Cmax Free drug/encapsulated drug  AUC0–t














Reference DXR HCl 
liposome injection 
(batch 2)
(c) Ratios of free to encapsulated DXR in Sprague–Dawley rats (4 mg/kg dose)
 Plasma 0.02 0.01 0.01 0.02 0.02 0.02
 Bone marrow 1.4 1.6 2.3 1.6 2.2 1.8
 Skin 1.2 0.8 1.5 3.3 2.0 2.0
 Kidney 0.7 0.4 0.3 1.4 1.0 0.7
 Heart 0.5 0.4 0.4 1.1 1.2 1.1
 Spleen 0.7 0.3 0.3 1.3 0.9 0.4
 Lung 0.3 0.2 0.3 0.2 0.1 0.1
 Liver 0.3 0.2 0.2 0.8 0.5 0.5
Tissues Free drug/encapsulated drug Cmax Free drug/encapsulated drug  AUC0–t














Reference DXR HCl 
liposome injection 
(lot 2)
(d) Ratios of free to encapsulated DXR in Sprague–Dawley rats (10 mg/kg dose)
 Plasma 0.01 0.01 0.01 0.02 0.02 0.02
 Bone marrow 2.9 2.7 5.0 3.5 4.4 5.9
 Skin 9.9 8.4 11.1 14.1 10.1 8.0
 Kidney 0.4 0.2 0.2 1.5 0.8 0.7
 Heart 0.7 0.6 0.6 1.3 1.2 1.2
 Spleen 0.7 0.6 0.4 2.4 1.9 1.0
 Lung 0.3 0.3 0.2 0.3 0.3 0.3
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same in plasma and the liver, compared with the reference 
DXR HCl liposome injection. Doxorubicinol is thought to 
be responsible for the cardiotoxicity associated with DXR. 
The SPIL DXR HCl liposome injection may therefore be 
less cardiotoxic in rats. However, we acknowledge that this 
observation may not carry over to humans, and may be the 
result of inherent biological variation within the test sys-
tem. There was also some evidence that the SPIL DXR HCl 
liposome injection leads to lower exposure of the cardio-
toxic metabolite doxorubicinol in the liver (where DXR is 
metabolised) and potentially in plasma of mice, compared 
with the reference DXR HCl liposome injection. Because 
DXR is metabolised in the liver, lower levels of doxorubi-
cinol in this tissue suggests that doxorubicinol should be 
lower in other tissues as well. This was not the case, so the 
doxorubicinol differences may be the result of inherent bio-
logical variation within the test system.
In conclusion, the plasma and tissue distribution pro-
files of the SPIL and reference DXR HCl liposome injec-
tions were shown to be generally comparable. Further stud-
ies, comparing the toxicology of SPIL DXR HCl liposome 
injection with  Caelyx® in murine models, will be published 
in the future.
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Table 2  (continued)
Tissues Free drug/encapsulated drug Cmax Free drug/encapsulated drug  AUC0–t














Reference DXR HCl 
liposome injection 
(lot 2)
 Liver 0.3 0.3 0.3 0.6 0.5 0.4
